Welcome
- Overview
- Faculty Profiles and Interests
- Support Personnel
- Laboratory Facilities
- NEWS & Announcements
- 2009-2010 Seminar Series
- 2010-2011 Seminar Series
- 2011-2012 Seminar Series
- 2012-2013 Seminar Series
- 2013-2014 Seminar Series
- Graduate Programs
- Current Students
- Student-Faculty Publications
- Recruitment
Rocket Science
About UT - Map to UT Health Science Campus
Related Links
- Cancer Biology Track
- 2011 Midwest DNA Symposium
- 2011 Graduate Research Forum
- 2010 Graduate Research Forum
- 2010 UT-COM Research Day
- Cancer Center
- Electron Microscopy Facility
- Flow Cytometry Core Lab
- Genomics Core Lab
- Advanced Microscopy & Imaging Center
Contact Us
Health Science Campus, Mail Stop #1010
3000 Arlington Avenue
Toledo, OH 43614
419-383-4131 phone
419-383-6228 fax
Kam C. Yeung, Ph.D.
![]() |
Kam C. Yeung, Ph.D. |
RESEARCH INTERESTS:
The major focus of our research program is to understand the molecular basis of cell
signaling on cellular as well as organismal levels. In metazoan each individual cell
is related to others by the interplay of numerous signaling pathways. Dyregulation
of signaling pathways often affects cellular homeostasis leading to different pathological
conditions including cancers. Ongoing projects include:
1. Regulation of RKIP protein interaction network
The project focuses on elucidating the function of Raf Kinase Inhibitor Protein, RKIP,
a novel kinase inhibitor that was identified as a potent tumor metastasis suppressor.
Mechanistically, this protein functions as a negative regulator of both the Raf and
NF-kB signaling pathways. In this project we will investigate three possible mechanisms
of RKIP regulation. We will investigate in detail the mechanism of RKIP regulation
by phosphorylation. The in vivo phosphorylation status of RKIP will be examined under a variety of physiological
conditions known to stimulate MAPK activity. We will examine the effects of phosphorylation
on the biological activities of RKIP towards its known targets. Several lines of
evidence indicate that RKIP contains a novel phospho amino acid binding motif. We
showed that RKIP bounds to phosphorylated residues on Raf-1. We will investigate
whether the phosphorylation/dephosphorylation of RKIP targets is a general mechanism
that governs RKIP interaction with its molecular partners. Finally we have identified
TRAF6 as a putative mediator of RKIP effect on NK-kB activation. A combination of
biochemical and genetics approach will be used to confirm its mediator function in vivo.
2. RKIP regulation as a potential for tumor suppression
Consistent with its inhibitory effects on the Raf and NF-kB signaling pathways, a
significant inverse correlation was observed between the expression of RKIP and the
stage of cancer development in prostate tumors. Importantly, restoration of RKIP
expression in highly metastatic prostate cancer cell lines sensitized them to apoptosis
and inhibited metastasis in a xenograft mouse model, suggesting this protein as a
promising candidate for cancer therapy. In order to exploit this potential, this
project proposes to define the transcription factors that regulate RKIP expression
and establish its tumor metastasis suppression function in vivo. Moreover, we will use tissue microarray (TMA) studies to determine the relationship
of the expression of RKIP to the putative regulators of RKIP expression in samples
from prostate cancer patients. We will also study in more depth the in vivo role of RKIP as a tumor metastasis suppressor, by exploring whether RKIP deficiency
is essential for or facilitates prostate cancer progression and metastasis in transgenic
mice.
EDUCATION:
B.Sc. 1986 Basic Medical Sciences, University of South Alabama, Mobile, AL
Ph.D. 1990 Microbiology, University of South Alabama, Mobile, AL
1990 - 1992 Post-Doc, Molecular Virology, University of Iowa, Iowa City, IA
1992 - 1996 Post-Doc, Biochemistry, Howard Hughes Medical Institute/UMDNJ, Piscataway,
NJ
ACADEMIC APPOINTMENTS:
2001-present Assistant Professor, Biochemistry & Cancer Biology, University of Toledo
Health Science Campus, Toledo, OH
1996-2001 Research Assistant Professor, Dept. of Molecular Biology, Cell Biology &
Biochemistry, Brown University, Providence, RI
REPRESENTATIVE PUBLICATIONS:
Ren, G., Feng, J., Datar, I.,Yeung, A.H., Saladi, S.V.,Feng, Y., de la Serna, I., and Yeung, K.C. (2012) A micro-RNA connection in BRaf(V600E)-mediatd premature senescence of human melanocytes. Int. J. Cell Biol. 2012:913242.
Yeung, K.C., Seitz, T., Li, S., Janosch, P., McFerran, B., Kaiser, C., Fee, F., Katsanakis, K.D., Rose, D.W., Mischak, H., Sedivy, J.M. and Kolch, W. (1999). Suppression of Raf-1 kinase activity and MAP kinase signaling by RKIP. Nature 401:173-177.
Yeung, K.C., Janosch, P., McFerran, B., Rose, D., Mischak, H., Sedivy, J.M. and Kolch,
W. (2000). The mechanism of suppression of the Raf/MEK/ERK pathway by the RKIP inhibitor
protein. Mol. Cell. Biol. 20:3079-3085.
Chatterjee, D., Schmitz, I., Krueger, A., Yeung, K.C., Kirchoff, S., Krammer, P.H.,
Peter, M.E., Wyche, J.H. and Pantazis, P. (2001). Induction of apoptosis in 9-nitrocamptothecin-treated
DU145 human prostate carcinoma cells correlates with de novo synthesis of CD95 and
CD95 ligand and down-regulation of c-FLIPshort. Cancer Res. 61:7148-7154.
Yeung, K.C., Rose, D.W., Dhillon, A.S., Yaros, D., Gustafsson, M., Chatterjee, D.,
McFerran, B., Wyche, J., Kolch, W. and Sedivy, J.M. (2001). Raf kinase inhibitor protein
interacts with NF-kB-inducing kinase and TAK1 and inhibits NF-kB activation. Mol. Cell. Biol. 21:7207-7217.
Hindley, A.D., Park, S., Wang, L., Shah, K., Wang, Y., Hu, X., Shokat, K.M., Kolch,
W., Sedivy, J.M. and Yeung, K.C. (2004) Engineering the serine/threonine protein kinase
Raf-1 to utilize an orthogonal analogue of ATP substituted at the N6 position. FEBS Lett. 556:26-34.
Chatterjee, D., Bai, Y., Wang, Z., Beach, S., Mott, S., Roy, R., Braastad, C., Sun,
Y., Mukhopadhyay, A., Aggarwal, B.B., Darnowski, J., Pantazis, P., Wyche, J., Fu,
Z., Kitagwa, Y., Keller, E.T., Sedivy, J.M. and Yeung, K.C. (2004) RKIP sensitizes
cancer cells to apoptosis. J. Biol. Chem. 279:17515-17523.
Keller, E.T., Fu, Z., Yeung, K.C. and Brennan, M. (2004) Raf kinase inhibitor protein:
A prostate cancer metastasis suppressor gene. Cancer Lett. 30:131-137.
Odabaei, G., Chatterjee, D., Jazirehi, A.L., Goodglick, L., Yeung, K.C. and Bonavida, B. (2004) Raf-1 kinase inhibitor protein (RKIP): Structure, function, regulation of cell signaling and pivotal role in apoptosis. Advances in Cancer Research 91:169-200.
Park, S., Yeung, M., Beach, S., Shield, J. and Yeung, K.C. (2004) RKIP down-regulates B-Raf kinase activity in melanoma cancer cells. Oncogene 24:3535-3540.
Park, S., Rath, O., Beach, S., Xiang, X., Kelly, S.M., Luo, Z., Kolch, W. and Yeung, K.C. (2006) Regulation of RKIP binding to the N-region of Raf-1 kinase. FEBS Lett. 580(27):6405-6412.
Theroux, S., Pereira, M., Casten, K.S., Burwell, R.D., Yeung, K.C., Sedivy, J.M. and Klysik, J. (2007) Raf kinase inhibitory protein knockout mice: Expression in the brain and olfaction deficit. Brain Res. Bull. 71(6):559-567.
Beach, S., Tang, H., Park, S., Dhillon, A.S., Keller, E.T., Kolch, W. and Yeung, K.C.
(2008) Snail is a repressor of RKIP transcription in metastatic prostate cancer cells.
Oncogene, 27:2343-2348.
McHenry, K., Montesano, R., Zhu, S., Beshir, A.B., Tang, H., Yeung, K.C. and Fenteany,
G. (2008) Raf kinase inhibitor protein positively regulates cell-substratum adhesion
while negatively regulating cell-cell adhesion. J. Cell. Biochem. 103(3):972-985.
Baritaki, S., Katsman, A., Chatterjee, D., Yeung, K.C, Spandidos, D.A. and Bonavida,
B. (2007) Regulation of tumor cell sensitivity to TRAIL-induced apoptosis by the metastatic
supppressor RKIP via YY1 inhibition and DR4 up-regulation. J. Immun., 179(8):5441-5453.
Rath, O., Park, S., Tang, H.H., Banfield, M.J., Brady, R.L., Lee, Y.C., Dignam, J.D.,
Sedivy, J.M., Kolch, W. and Yeung, K.C. (2008) The RKIP (Raf-1 Kinase Inhibitor Protein)
conserved pocket binds to the phosphorylated N-region of Raf-1 and inhibits the Raf-1-mediated
activated phosphorylation of MEK. Cell Signal, 20:935-941.
Bonavida, S., Baritaki, S., Huerta-Yepez, S., Vega, M.I., Chatterjee, D. and Yeung,
K.C. (2008) Novel therapeutic applications of Nitric Oxide donors in cancer: roles
in chemo- and immuno-sensitization to apoptosis and inhibition of metastases. Nitric Oxid: Biology and Chemistry, 19:152-157.
UT Virtual View Book
UT Rockets
A University Rising
UTMC Named Regions #1 Hospital
